JNJ Stock Traded 40% Over Value Despite Promising Multiple Myeloma Results
Johnson & Johnson (NYSE: JNJ) recently announced positive phase 3 trial results for its Tecvayli and Darzalex Faspro combination therapy in treating multiple myeloma patients who have had prior therapies. The treatment significantly improves outcomes, bringing 87% of patients to mortality risk levels comparable to the general population and extending median overall survival to four times that of traditional therapies.
The company's diversified operations span innovative medicines, including oncology, immunology, neuroscience, and cardiovascular therapies, as well as MedTech products used in various medical fields. With a market capitalization of $654.07 billion and approximately 138,200 employees worldwide, Johnson & Johnson is a global leader in health and well-being products.
Despite the promising results, GuruFocus estimates that JNJ's stock is 40.2% overvalued based on its GF Value™ metric. The company offers a dividend yield of 1.93%, supported by consistent dividend growth of 4.9% over the past three years and a moderate payout ratio of 55%. However, the premium valuation introduces caution for investors seeking reliable dividend income.
The stock's GF Score™ is strong at 83/100, driven by excellent profitability and solid financial health. However, momentum and valuation metrics are less favorable, reflecting the stock's elevated price and recent insider selling pressure. GuruFocus tracks 24 premium gurus holding JNJ shares, with a net reduction in positions recently as 14 gurus trimmed their stakes while only 5 added.